Business Wire

AL-SHADOWDRAGON

Share
ShadowDragon™ Releases The OSINT Platform, Horizon®

ShadowDragon™, a provider of ethical open-source intelligence (OSINT) software, unique datasets and APIs, is pleased to announce significant enhancements to its flagship Open-Source Intelligence Investigative platform Horizon®. These updates represent a milestone in the evolution of investigative technology, offering capabilities to streamline investigative processes and uncover valuable insights.

The OSINT Platform encompasses an all-in-one solution for investigations with unparalleled access to publicly available information, including geolocation data, platform monitoring, breach data and the ability to integrate external data streams. This allows for a modern approach to link analysis in one comprehensive toolkit. Horizon® offers access to more than 225 data collection sources, more than 1500 pivot points, and advanced, customizable link analysis capabilities.

Horizon® is accessible with any internet connection and allows users to access critical data and conduct investigations from any device, providing unprecedented flexibility and mobility. Mapping advancements, plotting capability, visual geofencing, and geoestimation allow for different starting points that pinpoint precise locations and uncover valuable insights. Horizon® offers unmatched ease of integration, creating tailored data streams able to solve for any problem set. Horizon® will also enable analysts the ability to work on the go from a tablet, phone, or desktop/laptop.

Horizon®, coupled with ShadowDragon’s SocialNet ® offers a powerful OSINT toolkit that includes more than 225 data collection sources to use for correlating publicly available data, integrated brand monitoring, breach data inquiries, social media information and link analysis capabilities to empower users with a holistic approach to investigations. Users benefit from advanced link analysis capabilities, allowing them to connect the dots and uncover actionable intelligence with ease.

CEO Daniel Clemens said, “Our customers have asked for a unified platform for many years. We are answering their requests with Horizon®, enabling customers to use our platform and data with their existing tools, easily import and export data, while enabling greater focus for complex analysis of data. The Horizon® Platform allows publicly available data to tell the story for the analyst. I am very delighted at what our team has produced and thankful to how our tools help protect many on a global scale.”

“You guys are doing incredible things with SocialNet® and Horizon®. Looking back as a user of Horizon's early release, it has been the coolest privilege to experience the last three years of innovation, watching the platform evolve and morph with every incremental update, and knowing there are always more tweaks still in the works.” - Law Enforcement Customer.

These updates underscore ShadowDragon's commitment to innovation and excellence in the field of investigative technology. By continuously enhancing its OSINT suite with new features, data collection sources and capabilities, ShadowDragon aims to empower investigators with the tools they need to stay ahead of emerging threats and make informed decisions.

Nico Dekens, ShadowDragon Director of Intelligence, said, "This is as close as one can get to having a silver bullet solution that helps solve investigative and analytical needs. This means that no matter what OSINT expertise you have, ShadowDragon's technology will speed up your investigation through an initiative platform. But it is not limited to just the platform and tools, the seasoned team will train you on usage and will support you in getting the most out of your investigative needs. The newly released features and capabilities will make your work future proof and will speed up ANY investigation significantly."

For more information about the ShadowDragon™ suite of OSINT tools and capabilities, such as SocialNet®, OIMonitor®, MalNet®, and Horizon®, click here.

About ShadowDragon

ShadowDragon™ provides comprehensive, cyber investigative resources and training for use by private companies, intelligence gathering professionals, law enforcement, and government. The U.S.-based company delivers open source intelligence (OSINT) from over 225 networks including social media platforms, chat rooms, forums, historical datasets, and the dark web. The company monitors malware history, data breach dumps, and other areas for active cyber threats. These data collection and analytic tools help defend against malicious acts in the digital and physical world. For more information, visit www.shadowdragon.io. Visit the ShadowDragon Trust Center for details about the company’s approach to “OSINT for Good”.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240413210644/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye